Press Releases

 
Press Releases
  Date Title and Summary View
Sep 25, 2017
Phase 2, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, an immune checkpoint inhibitor, along with gemcitabine/ABRAXANE® (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE® versus gemcitabine/ABRAXANE® AMES, Iowa...
Sep 7, 2017
Pivotal Trial of Indoximod in Advanced Melanoma to Include Both PD-1 Inhibitors, KEYTRUDA (pembrolizumab) and OPDIVO® (nivolumab) AMES, Iowa--(BUSINESS WIRE)-- NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 stu...
Aug 29, 2017
AMES, Iowa, Aug. 29, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September: Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York CityCantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New...
Jul 28, 2017
AMES, Iowa, July 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the second quarter of 2017 and provided updates on its clinical development program for indoximod, NewLink Genetics' small molecule targeting the IDO pathway with a distinct mechanism of action. "We conti...
Jul 27, 2017
AMES, Iowa, July 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced first patient dosed in the Phase 1 study of NLG802, a novel prodrug of indoximod.  NLG802 is an investigational agent targeting the IDO pathway and represents an important step in the company's strategic planning and intellectual property (IP)...
Jul 10, 2017
AMES, Iowa, July 10, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it has received a Notice of Allowance for U.S. patent application number 15/171,031 from the United States Patent and Trademark Office (USPTO) covering claims to the salts and prodrugs of indoximod (1-methyl-D-tryptophan). Indoximod is Ne...
Jul 7, 2017
AMES, Iowa, July 07, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its second quarter 2017 financial results on Friday, July 28, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development acti...
Jun 23, 2017
AMES, Iowa, June 23, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from the Phase 1b portion of a study of indoximod, an IDO pathway inhibitor, in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia (AML).  Abstract E-912, Indoximod in C...
Jun 8, 2017
AMES, Iowa, June 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that on June 6, 2017, Genentech, a member of the Roche Group, informed NewLink Genetics that it intends to return the rights to IDO inhibitor GDC-0919 (navoximod) pursuant to the License Agreement dated October 16, 2014. As a consequence of su...
Jun 5, 2017
AMES, Iowa, June 05, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announces the presentation of results from a randomized Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with metastatic castration resistant prostate cancer.  ...
Page:
1
... NextLast
= add release to Briefcase